N-acetyl transferase-2 and bladder cancer risk: A meta-analysis

Johns, Louise; Houlston, Richard S.

doi:10.1002/1098-2280(2000)36:3<221::aid-em5>3.0.co;2-q

Cited by 46 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the decrease in smoking rates in the US, the age-adjusted incidence rates for bladder cancer in men and women have remained the same or have marginally increased since the 1980s (5). Genetic polymorphisms in a number of metabolic enzymes were found to act as modulators of bladder cancer risk (6,7).…”

Section: Introductionmentioning

confidence: 99%

Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk

Yang

Zhang

Song

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Vascular endothelial growth factor (VEGF) gene polymorphisms are associated with susceptibility to a number of cancers. The present case-controlled study aimed to investigate the correlation between VEGF gene polymorphisms and the risk of bladder cancer. The effects of VEGF polymorphisms were investigated in patients with bladder cancer and healthy controls in our hospital between May, 2008 and May, 2013. Peripheral blood samples were obtained from 480 patients with bladder cancer and 420 healthy controls. The polymerase chain reaction-restriction fragment length polymorphism technique was used to detect three VEGF gene polymorphisms (rs3025039 C̸T, rs833052 C̸A and rs1570360 G̸A) in these subjects. The genotype and allele frequencies were also investigated in order to determine their association with stage, grade and histological type of bladder cancer, as well as smoking status. Our results suggested that the frequency of the rs833052 AA genotype was significantly higher in patients with bladder cancer [odds ratio (OR)=1.75; 95% confidence interval (CI): 1.05-2.92; P=0.03] compared to that in healthy controls. There was no significant correlation between the rs833052 AA genotype and bladder cancer stage, grade or histological type, whereas smoking was identified as a risk factor for bladder cancer in the included patients (OR=1.48; 95% CI: 1.13-1.93; P=0.004). The rs3025039 and rs1570360 gene polymorphisms were not found to be correlated with the risk of bladder cancer or its progression. In conclusion, our results suggested that the VEGF rs833052 C̸A polymorphism may be associated with a modest increase in the risk of bladder cancer in Chinese individuals.

show abstract

Section: Introductionmentioning

confidence: 99%

Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk

Yang

Zhang

Song

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Accordingly, recent NAT2 genotype studies show associations with urinary bladder cancer that are highest for particular NAT2 alleles associated with slow acetylator phenotypes, consistent with earlier phenotypic studies (Cartwright et al 1982). Some meta-analyses of case-control studies that investigated associations between NAT2 and bladder cancer were reported and a weak interaction between smoking and NAT2 slow acetylation was observed (Green et al 2000;Johns and Houlston 2000;Marcus et al 2000a;Marcus et al 2000b). Evidence linking elevated CYP1A2 activity to increased bladder cancer risk has been reported (Kaderlik and Kadlubar 1995;Lee et al 1994).…”

Section: Introductionmentioning

confidence: 99%

Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer

Tsukino

Kuroda

Nakao

et al. 2004

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Inherited interindividual variation for the drugs such as isoniazid and sulphamethazine is due to the NAT2 acetylation polymorphism (Smith et al, 1995;Hivonen, 1999). Individuals can be classified as slow and/or fast acetylators, according to the activity of this enzyme and these drugs can be used as probes to determine NAT2 acetylation phenotype (Johns and Houlston, 2000). AT2 acetylation phenotype can be determined by dosing the subjects with specific probe drug such as sulphamethazine and then measuring the acetyl metabolites in urine or plasma to categorized the subject as ''slow'' or ''fast'' acetylator (Ognjanovic et al, 2006).…”

Section: Introductionmentioning

confidence: 61%

A gender wise study of arylamine N-acetyltransferase 2 (NAT2) acetylation phenotyping using sulphamethazine by high-pressure liquid chromatography (HPLC) assay

Akhter¹

2011

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

The acetylation polymorphism is one of the most common inherited variations in the biotransformation of drugs and chemicals and large number of studies has been done to determine the distribution of acetylator phenotypes among populations of different geographic origin. The aim of this study was to investigate the acetylator phenotypes of the Pakistani population and compare it between male and female healthy volunteers. The polymorphic acetylation of sulphamethazine has been investigated in male and female volunteers (50 each) of Pakistani population. Sulphamethazine was administered orally in Capsule form as 500 mg to each healthy male and female volunteer. Sulphamethazine and acetylsulphamethazine were determined in the six hour plasma samples by high-pressure liquid chromatography (HPLC). Acetylator phenotype was determined from the metabolic ratio of acetylsulphamethazine to sulphamethazine in the plasma samples. The acetylation of sulphamethazine by arylamine N-acetyltransferase 2 (NAT2) showed bimodal population frequency distribution. 60% of the female volunteers were found to be fast and 40% to be slow acetylators while that of male volunteers were 62% fast and 38% slow acetylators.

show abstract

N-acetyl transferase-2 and bladder cancer risk: A meta-analysis

Cited by 46 publications

References 31 publications

Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk

Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk

Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer

A gender wise study of arylamine N-acetyltransferase 2 (NAT2) acetylation phenotyping using sulphamethazine by high-pressure liquid chromatography (HPLC) assay

Contact Info

Product

Resources

About